Regeneron Pharmaceuticals’ (REGN) “Buy” Rating Reaffirmed at Canaccord Genuity Group

Canaccord Genuity Group reissued their buy rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report report published on Thursday morning, Benzinga reports. They currently have a $1,152.00 price objective on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the stock. Argus raised their price objective on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a buy rating in a research report on Tuesday, June 25th. Bank of America upped their price objective on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an underperform rating in a report on Friday, April 12th. Truist Financial reiterated a buy rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. Evercore ISI assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They issued an outperform rating and a $1,150.00 target price for the company. Finally, UBS Group lifted their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a buy rating in a research note on Wednesday, April 17th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of Moderate Buy and a consensus target price of $1,027.55.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $1,051.03 on Thursday. The firm has a 50 day moving average of $984.27 and a 200-day moving average of $951.53. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $115.81 billion, a P/E ratio of 31.05, a price-to-earnings-growth ratio of 2.17 and a beta of 0.13. Regeneron Pharmaceuticals has a 12 month low of $688.52 and a 12 month high of $1,081.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The firm had revenue of $3.15 billion for the quarter, compared to analysts’ expectations of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. As a group, sell-side analysts predict that Regeneron Pharmaceuticals will post 37.23 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Leonard S. Schleifer sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the transaction, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at $399,729,850. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 22,830 shares of the firm’s stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $979.23, for a total value of $22,355,820.90. Following the completion of the sale, the chief executive officer now directly owns 466,877 shares in the company, valued at $457,179,964.71. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Leonard S. Schleifer sold 25,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the sale, the chief executive officer now directly owns 408,200 shares in the company, valued at $399,729,850. The disclosure for this sale can be found here. In the last 90 days, insiders sold 61,971 shares of company stock worth $61,217,654. 7.48% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Sierra Summit Advisors LLC bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth $1,011,000. Dynamic Technology Lab Private Ltd purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $749,000. Public Employees Retirement Association of Colorado boosted its stake in Regeneron Pharmaceuticals by 16.0% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 16,074 shares of the biopharmaceutical company’s stock worth $14,118,000 after acquiring an additional 2,220 shares in the last quarter. Exchange Traded Concepts LLC boosted its stake in Regeneron Pharmaceuticals by 32.7% during the fourth quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock worth $4,351,000 after acquiring an additional 1,221 shares in the last quarter. Finally, Congress Wealth Management LLC DE bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $271,000. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.